guiding you onto the right path

Latest Jobs

Purpose: Acting as the key interface with clients over projects, manages the timely delivery of project outputs in line with client expectations. Dev...
Purpose: Manages the delivery of client project(s), ensuring delivery of the project in line with client objectives and expectations as well as proje...

Principal, Offering development & Strategy

Overview of the role

 

The candidate would be responsible for developing innovative product offerings and initial product go to market across  businesses, leveraging latest innovation in technology to develop value added solutions. Innovative technologies such in data processing, semantics, analytics, machine learning, natural language processing, scientific methods & modelling, or data visualization are being or expected to be applied across ongoing product portfolio. A successful candidate will be able to identify business opportunities for these technologies, initiate projects and build investment cases, and coordinate across business units and functions to turn concepts into tangible product offerings. The role will involve significant exposure to senior business unit leaders and CEO direct reports as well as senior clients.  

 

 

RESPONSIBILITIES

 

  • Identify new opportunities to address market needs for health informatics products
  • Consult with customers to fully understand their needs, develop high quality proposals, leveraging the broad organization, to address these and navigate organizations to close the business.
  • Assume principal responsibility for delivery product development, through direct oversight and by ensuring content experts are in-place and on-track.
  • Engage closely and supervise cross-functional teams to ensure the full complement of capabilities & solutions reach customers.
  • Contribute to the development of thought leadership agenda and innovation agenda
  • Own thought leadership in the specific technology or solution areas
  • Build and maintain external stakeholders’ relationships to promote market positioning, access to data and relationships with key influencing groups
  • Lead client and other engagement to refine product offering in Europe and the US, supported by colleagues where appropriate
  • Have responsibility for line management, coaching, mentoring and development of employees and participate in recruitment.
  • Take a leadership role in implementing RWES business vision and objectives and supporting the strategic development of the business.

 

 

Project development responsibilities

 

  • Lead teams of professionals in the design, development and delivery of complex RWES products to a high standard which meet or exceed client expectations
  • Provide high level input to and ensure that the design, structure and delivery of products are appropriate to the characteristics and needs of the client
  • Oversee the development of product development plans which ensure successful completion, on-time and on-budget, from start to finish
  • Recommend improvements and alternative solutions to resolve problems
  • Engage technology teams to define IT requirements, build plans
  • Provide coaching, technical training and direction to more junior professionals assigned engagements and across multiple projects

 

 

QUALIFICATIONS & EXPERIENCE

 

Qualifications

 

  • BA/BSc in life sciences or information technology discipline
  • A postgraduate qualification in life sciences or information technology discipline

 

Experience

  • Leadership experience in Healthcare with focus on data, technology and analytics including working with senior clients
  • Experience in product development, ideally from initial concept development and market sizing through to product delivery plans
  • Proven ability to advance ambiguous or conceptual ideas and engage multiple stakeholders, internal and clients, to decision points
  • Track records of thought leadership

 

TECHNICAL AND PERSONAL SKILLLS

 

Technical skills and knowledge – essential

 

  • Good understanding of analyses conducted in healthcare databases
  • Overall understanding of different technology domains (infrastructure, architecture, analytics applications) and experience of managing technology programs
  • Proven hands-on leadership in at least one innovative technology area relevant to healthcare
  • Knowledge of the scientific method in the medical domain or broader social science
  • Competency in using Word and PowerPoint and developing clear storylines
  • Knowledge of consulting methods, tools and techniques
  • Commercial awareness and good understanding of the health care, health technology and pharmaceutical industry, gained through experience
  • Understanding of and interest in the international health care environment and direct experience and 2 or more countries

 

Personal skills and behaviours

 

  • Capable of closing large client proposals or internal projects, including being able to influence decision makers.
  • The ability to take on a leadership role within the organisation and to take the initiative in working situations generally.
  • A commitment to navigating and working collaboratively and effectively with others throughout the organisation to accomplish goals.
  • Excellent communication and influencing skills and an ability to build strong business relationships.
  • Fluency in English and excellent oral presentation and writing skills
Job Type:
Permanent
Experience:
Bachelors Degree
Location:
Europe
Sector:
Health Economics & Outcomes Research
Salary:
£Negotiable
Ref:
110

How to apply

Apply Now

Latest News

Fri, 13 Jun 2025 10:00:00 +0200
A series of digital tests, carried out via a smartphone app, could enhance the detection of disease progression in Huntington's disease and improve the efficiency of clinical trials, finds research led by scientists at University College London (UCL) and Roche.

The research, published in Brain, highlights how digitising tests designed to measure the progression of motor symptoms in people with Huntington's disease can provide a sensitive and reliable way to track changes in the function of patients.

Thu, 12 Jun 2025 10:00:00 +0200
BayerVividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, announced it has secured exclusive worldwide rights to develop and commercialize the clinical-stage Werner helicase (WRN) covalent inhibitor VVD-214 (RO7589831), strengthening and complementing its innovative oncology development pipeline. VVD-214 was discovered and developed under an exclusive worldwide collaboration and license agreement initiated between Vividion and Roche in 2020.
Wed, 11 Jun 2025 10:00:00 +0200
We have all heard of antibodies - proteins produced by our bodies to bind to viruses or bacteria, marking them for elimination by the immune system. But not all of us are familiar with aptamers: short segments of DNA or RNA that are designed to bind, like antibodies, to specific targets. Synthetic and inexpensive to produce, aptamers are attractive alternatives to antibodies for biomedical diagnostics and therapeutics.
Tue, 10 Jun 2025 10:00:00 +0200
Food scientists at the University of Illinois Urbana-Champaign identified the optimal fermentation conditions for pulses - the dried edible seeds of legumes - that increased their antioxidant and antidiabetic properties and their soluble protein content.

Using the bacteria Lactiplantibacillus plantarum 299v as the microorganism, the team fermented pulses obtained from varying concentrations of black bean, black-eyed pea, green split pea, red lentil and pinto bean flours.

Mon, 09 Jun 2025 10:00:00 +0200
In the quest to design vaccines that better help the body's immune system fight disease, scientists are always looking for more tools for their arsenal. The strong antibody responses generated by vaccines provide an important first round of defense, but "you always want to have a backup plan," says Biomedical Graduate Studies Ph.D. student Emily A. Aunins, considering viruses mutate to evade antibody responses that become widespread in a population.
Fri, 06 Jun 2025 10:00:00 +0200
SanofiNew data from 18 abstracts, including five oral presentations, will be presented at the 33rd congress of the International Society on Thrombosis and Haemostasis (ISTH) in Washington D.C., US from June 21 to 25, 2025, highlighting Sanofi as a leader in hemophilia committed to rare blood diseases. Data to be presented expand on the potential of rilzabrutinib to address the underlying immune dysregulation of immune thrombocytopenia (ITP) and strengthen Sanofi as a leader in hemophilia with ALTUVIIIO and the newly launched Qfitlia, aimed at providing more treatment options to help improve patients' lives.
Thu, 05 Jun 2025 10:00:00 +0200
Results from a new clinical trial suggest that a high-fiber plant-based diet could benefit patients at risk for developing multiple myeloma, the second most common type of blood cancer. The study showed that the diet was not only feasible and well-received but also improved several factors that could potentially delay the progression of precancerous conditions that can lead to multiple myeloma.
Wed, 04 Jun 2025 10:00:00 +0200
University of Otago - Ōtākou Whakaihu Waka researchers have been part of two groundbreaking studies in the battle against drug resistant strains of Mycobacterium tuberculosis, the cause of tuberculosis.

Co-author on both studies, Dr Matthew McNeil, of the Department of Microbiology and Immunology, describes tuberculosis as a "massive public health problem" that is challenging to solve.

Tue, 03 Jun 2025 10:00:00 +0200
New research has found that those who consume a diverse range of foods rich in flavonoids, such as tea, berries, dark chocolate, and apples, could lower their risk of developing serious health conditions and have the potential to live longer.

The study was led by a team of researchers from Queen's University Belfast, Edith Cowan University Perth (ECU), and the Medical University of Vienna.

Mon, 02 Jun 2025 10:00:00 +0200
Understanding and preventing drug side effects holds a profound influence on drug development and utilization, profoundly impacting patients' physical and mental well-being. Traditional artificial drug experimentation methods are not only expensive but also time-consuming, rendering comprehensive testing a challenging task.
Fri, 30 May 2025 10:00:00 +0200
A joint research team from The Hong Kong University of Science and Technology and The Hong Kong University of Science and Technology (Guangzhou) has published a perspective article in MedComm - Future Medicine. The article comprehensively evaluates DeepSeek-R1, a Chinese-developed open-source large language model (LLM), and its potential to transform the healthcare landscape.
Thu, 29 May 2025 10:00:00 +0200
BayerBayer announced that the investigational compound sevabertinib (BAY 2927088) has been granted Priority Review status by the US Food and Drug Administration (FDA) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumors have activating human epidermal growth factor receptor 2 (HER2/ERBB2) mutations and who have received a prior systemic therapy.[1] Sevabertinib is an oral, small molecule, tyrosine kinase inhibitor (TKI).
Wed, 28 May 2025 10:00:00 +0200
A study led by a physician-scientist at the University of Arizona College of Medicine - Tucson's Sarver Heart Center identified a drug candidate that appears to reverse the progression of a type of heart failure in mouse models, which could lead to expanded treatment options for humans. The results were published in the journal Cell Metabolism.
Tue, 27 May 2025 10:00:00 +0200
Worldwide, more than 55 million people suffer from dementia caused by Alzheimer's Disease (AD) and other conditions that destroy cells in the brain and nervous system.

While there is no treatment to control or manage these neurodegenerative conditions, investigators at Case Western Reserve University, University Hospitals and the Louis Stokes Cleveland VA Medical Center have identified a new and promising drug to treat AD.

Mon, 26 May 2025 10:00:00 +0200
A widely used antidepressant drug could help the immune system fight cancer, according to a new UCLA research study.

Selective serotonin reuptake inhibitors, or SSRIs, significantly enhanced the ability of T cells to fight cancer and suppressed tumor growth across a range of cancer types in both mouse and human tumor models, the study, published in Cell, found.

Fri, 23 May 2025 10:00:00 +0200
PfizerPfizer Inc. (NYSE: PFE) announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese biopharmaceutical company, for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, currently undergoing several clinical trials in China for non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors.
Thu, 22 May 2025 10:00:00 +0200
As researchers work to improve treatment of Alzheimer's disease, new research by UCLA Health identified a candidate drug that reduces levels of a toxic form of a protein in the brain caused by the disease and improved memory in mice by boosting production of a protective protein.

In a study published in the Nature journal npj Drug Discovery, UCLA Health researchers targeted the protein clusterin (CLU), which is crucial in preventing the build-up of amyloid-beta plaques and

Wed, 21 May 2025 10:00:00 +0200
Purdue University's College of Pharmacy is now home to the Center for Research Innovation in Biotechnology and the Clinical Drug Experience Knowledgebase (CDEK), a comprehensive database of every active pharmaceutical ingredient with evidence of clinical testing.

The center, or CRIB, is a collaborative effort between Purdue and Stony Brook universities.

Tue, 20 May 2025 10:00:00 +0200
A drug used to treat type 2 diabetes may also be effective in slowing the progression of prostate cancer. This is shown by an international study in which researchers at Umeå University, Sweden, have participated. The researchers have found that drugs that regulate a particular protein have a key role in reducing prostate cancer recurrence among diabetic patients.
Mon, 19 May 2025 10:00:00 +0200
Using advanced artificial intelligence (AI), researchers have developed a novel method to make drug development faster and more efficient.

In a new paper, Xia Ning, lead author of the study and a professor of biomedical informatics and computer science and engineering at The Ohio State University, introduces DiffSMol, a generative AI model capable of generating realistic 3D structures of small molecules that can serve as promising drug candidates.

Upload Your CV

Need help finding that new job? Leave your details with us and request a call back from one of our consultants.

Submit A Vacancy

Looking to expand? Or a vacancy has become available in your business then let us know and we can find the right person for you